CCR7 and non-Hodgkin lymphoma: CAP-100 (NCT04704323) and JBH492 (NCT04240704), monoclonal antibodies against CCR7, have been involved in Phase I clinical trials for Chronic lymphocytic leukemia and Non-Hodgkin lymphoma.